The influence of treatment with the dihydropyridine-type Ca2+ antagonist lercanidipine on heart and coronary microanatomic changes was investigated in spontaneously hypertensive rats, Cohen-diabetic rats, and Cohen-Rosenthal diabetic hypertensive rats. At 12 weeks of age, animals were left untreated (control groups) or were treated for 8 weeks with an oral dose of 3 mg/kg per day of lercanidipine. Wistar-Kyoto rats were used as a normotensive reference group. In spontaneously hypertensive rats and diabetic hypertensive rats, systolic blood pressure was higher in comparison with Wistar-Kyoto rats. Augmented pressure values were decreased by lercanidipine treatment. Systolic blood pressure was slightly higher in Cohen-diabetic rats than in Wistar-Kyoto rats, and this increase was countered by treatment with lercanidipine. In spontaneously hypertensive rats, diabetic rats, and diabetic hypertensive rats, the thickness of left ventricle and cardiocyte area were increased. Focal connective tissue areas and diffuse accumulation of connective tissue were observed in the left ventricle of spontaneously hypertensive and Cohen-diabetic rats, respectively. Pharmacological treatment countered left ventricle thickening and restored cardiocyte area values in subendocardium. An increased thickness of tunica media accompanied by luminal narrowing was found in coronary artery branches of control spontaneously hypertensive and diabetic hypertensive rats. Treatment with lercanidipine countered vascular changes primarily in small-sized coronary arteries. These results indicate that hypertensive, diabetic, and diabetic hypertensive rats undergo cardiac hypertrophy and vascular changes affecting small-sized coronary arteries. Treatment with lercanidipine countered hypertension-related cardiac and coronary changes, suggesting that this dihydropyridine-type Ca2+ antagonist may improve heart and coronary structure in diabetes associated with hypertension.

译文

:在自发性高血压大鼠,Cohen-糖尿病大鼠和Cohen-Rosenthal糖尿病高血压大鼠中,研究了用二氢吡啶类Ca2拮抗剂乐卡地平治疗对心脏和冠状动脉微解剖学变化的影响。在12周大时,动物不予治疗(对照组)或以每天3 mg / kg的lercanidipine口服剂量治疗8周。 Wistar-Kyoto大鼠用作血压正常对照组。与Wistar-Kyoto大鼠相比,自发性高血压大鼠和糖尿病性高血压大鼠的收缩压更高。乐卡地平治疗可增加压力值。 Cohen-糖尿病大鼠的收缩压略高于Wistar-Kyoto大鼠,而这种增加可以通过用lercanidipine治疗来抵消。在自发性高血压大鼠,糖尿病大鼠和糖尿病性高血压大鼠中,左心室厚度和心肌细胞面积增加。自发性高血压和科恩-糖尿病大鼠的左心室分别观察到局灶性结缔组织区域和结缔组织的弥漫性积聚。药物治疗可抵抗心内膜下左心室增厚和恢复心肌细胞面积值。在自发性高血压和糖尿病性高血压大鼠的冠状动脉分支中发现中膜厚度增加并伴有腔狭窄。乐卡地平的治疗主要在小型冠状动脉中抵抗血管变化。这些结果表明,高血压,糖尿病和糖尿病高血压大鼠经历心脏肥大和血管变化,影响了小冠状动脉。乐卡地平的治疗可对抗高血压相关的心脏和冠状动脉变化,提示这种二氢吡啶类Ca2拮抗剂可改善与高血压相关的糖尿病患者的心脏和冠状动脉结构。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录